AbbVie Inc. (ABBV) Earnings Before Tax (EBT)
The ebt for AbbVie Inc. (ABBV) is $6.60 Billion with a year-over-year change of +77.53%. Earnings Before Tax (EBT), also called pre-tax income, represents a company's profit after all operating and non-operating expenses but before income tax expense.
ABBV EBT Chart
Current EBT
$6.60B
$6.60 Billion
Year-over-Year Change
+77.53%
vs. $3.72B prior year
Historical Data
17
Years of data available
Annual EBT History
| Year | EBT | YoY Change | % Change |
|---|---|---|---|
| 2025 | $6.60B | +$2.88B | +77.53% |
| 2024 | $3.72B | $-2.53B | -40.54% |
| 2023 | $6.25B | $-7.23B | -53.62% |
| 2022 | $13.48B | +$488.00M | +3.76% |
| 2021 | $12.99B | +$9.59B | +282.25% |
| 2020 | $3.40B | $-5.03B | -59.67% |
| 2019 | $8.43B | +$3.23B | +62.13% |
| 2018 | $5.20B | $-2.53B | -32.74% |
| 2017 | $7.73B | $-157.00M | -1.99% |
| 2016 | $7.88B | +$1.24B | +18.65% |
| 2015 | $6.64B | +$4.28B | +180.50% |
| 2014 | $2.37B | $-2.96B | -55.57% |
| 2013 | $5.33B | $-393.00M | -6.86% |
| 2012 | $5.72B | +$2.06B | +56.08% |
| 2011 | $3.67B | $-1.17B | -24.15% |
| 2010 | $4.84B | $-1.11B | -18.73% |
| 2009 | $5.95B | — | — |
About AbbVie Inc.
AbbVie Inc. is a global biopharmaceutical company dedicated to the discovery, development, manufacturing, and commercialization of advanced medicines. Its extensive therapeutic portfolio encompasses several key areas: Immunology and Inflammation: Leading products include HUMIRA, an injectable therapy for autoimmune and intestinal Behçet's diseases; SKYRIZI, which addresses moderate to severe plaque psoriasis in adults; and RINVOQ, a JAK inhibitor for moderate to severe active rheumatoid arthritis in adult patients. Oncology and Hematology: For blood cancers, AbbVie provides IMBRUVICA and VENCLEXTA (a BCL-2 inhibitor), both indicated for adult patients with chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). Virology: MAVYRET offers a treatment option for individuals with chronic HCV genotype 1-6 infection. Gastroenterology and Endocrinology: The company supplies CREON, an enzyme replacement therapy for exocrine pancreatic insufficiency, and Synthroid, used to manage hypothyroidism. Linzess/Constella helps treat irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation. Women's Health and Urology: Lupron serves as a palliative treatment for conditions like advanced prostate cancer, endometriosis, central precocious puberty, and anemia caused by uterine fibroids. ORILISSA, a nonpeptide small molecule GnRH antagonist, is designed for women experiencing moderate to severe endometriosis pain. Neurology: AbbVie offers Duopa and Duodopa, a levodopa-carbidopa intestinal gel for Parkinson's disease, and Ubrelvy to treat migraines (with or without aura) in adults. The therapeutic formulation of Botox is also part of its offerings. Ophthalmology: Its eye care segment features Lumigan/Ganfort (a bimatoprost ophthalmic solution) and Alphagan/Combigan (an alpha-adrenergic receptor agonist), both aimed at reducing elevated intraocular pressure (IOP) in patients with open-angle glaucoma (OAG) or ocular hypertension. Restasis, a calcineurin inhibitor immunosuppressant, is provided to enhance tear production, alongside other specialized eye care products. AbbVie Inc. also engages in research collaborations, including a partnership with Dragonfly Therapeutics, Inc. The company was founded in 2012 and operates from its headquarters in North Chicago, Illinois.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- CEO
- Robert A. Michael